Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 9/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26418968 | 0.86 | HRH3 (0.49) | TMEM97SIGMAR1KCNH2KDM4ENPC1 | |
| SCHEMBL21140748 | 0.86 | HRH3 (0.45) | TMEM97SIGMAR1KCNH2KDM4ENPC1 | |
| SCHEMBL22993219 | 0.84 | TMEM97 (0.44) | TMEM97SIGMAR1KCNH2MEN1KMT2A | |
| SCHEMBL26419000 | 0.79 | TMEM97 (0.33) | TMEM97SIGMAR1KCNH2KDM4ENPC1 | |
| SCHEMBL12681585 | 0.79 | KDM4E (0.39) | TMEM97SIGMAR1KCNH2KDM4ENPC1 | |
| SCHEMBL12141678 | 0.79 | SLC6A2 (0.50) | TMEM97SIGMAR1KCNH2KDM4ENPC1 | |
| SCHEMBL26167901 | 0.77 | KCNH2 (0.40) | TMEM97SIGMAR1KCNH2MEN1KMT2A | |
| SCHEMBL20350285 | 0.77 | HRH3 (0.50) | KDM4E | |
| SCHEMBL15893964 | 0.77 | HSP90AA1 (0.53) | KDM4E | |
| SCHEMBL27305602 | 0.77 | NPC1 (0.43) | TMEM97SIGMAR1KCNH2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2023081759-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-20210221814-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. | 2021-07-22 | — | — | US | disclosed |
| WO-2021028645-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028649-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| US-20080221094-A1 | Metalloprotease inhibitors containing a squaramide moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | TMEM97 2299/4885SIGMAR1 4553/4885KCNH2 4649/4885 |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | TMEM97 4834/4885SIGMAR1 4880/4885KCNH2 2982/4885 |
| US-20210221814-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | TMEM97 4837/4885SIGMAR1 4879/4885KCNH2 3169/4885 |
| US-20080221094-A1 | Metalloprotease inhibitors containing a squaramide moiety | MMP13, MMP14, MMP11 | TMEM97 4764/4885SIGMAR1 4586/4885KCNH2 4022/4885 |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | TMEM97 4834/4885SIGMAR1 4880/4885KCNH2 2982/4885 |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | TMEM97 710/4885SIGMAR1 3180/4885KCNH2 4719/4885 |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | TMEM97 2325/4885SIGMAR1 4538/4885KCNH2 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.